Medical Information Response

Wegovy® (semaglutide) injection Dosing – Guidelines

Summary

- **Wegovy® should be initiated at a dose of 0.25 mg once weekly for 4 weeks.[1]** The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached (**Figure 1**).
    - If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.[1]
    - If adult patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks.[1] After 4 weeks, increase Wegovy® to the maintenance 2.4 mg once-weekly dose. Discontinue Wegovy® if adult patients cannot tolerate the 2.4 mg dose.
    - If pediatric patients aged 12 years and older do not tolerate the maintenance 2.4 mg once-weekly dose, the maintenance dose may be reduced to 1.7 mg once-weekly.[1] Discontinue Wegovy® if the patient cannot tolerate the 1.7 mg dose.
    - Novo Nordisk does not recommend a dose escalation schedule other than what is outlined in the Wegovy® Prescribing Information.
- Wegovy® should be administered as a once-weekly subcutaneous injection on the same day each week, at any time of day, with or without meals.[1] Wegovy® should be administered subcutaneously in the abdomen, thigh or upper arm.
- The maximum recommended dose of Wegovy® is 2.4 mg once-weekly.[1]
- At this time, Novo Nordisk does not have a specific recommendation on dosage adjustments during the discontinuation of Wegovy®.
- For information on using the Wegovy® pen, please refer to the Instructions for Use.

Prescribing Information

Section 1: Indications and Usage

- Wegovy® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in[1]:
    - Adults with an initial body mass index (BMI) of 30 kg/m^2 or greater (obesity), or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes [T2D], or dyslipidemia).[1]
    - Pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity).[1]

Section 2.1: Dosage and Administration, Patient Selection

- Select adult patients for Wegovy® treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management based on their BMI. BMI is calculated by dividing weight (in kilograms) by height (in meters) squared.[1]

- Select pediatric patients aged 12 years and older for Wegovy® treatment as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management based on BMI values and the Centers for Disease Control and Prevention (CDC) BMI cut-offs for obesity in pediatric patients.[1] Please see **Appendix A** for BMI cut-offs for obesity by sex and age for pediatric patients aged 12 years and older (CDC Criteria).

Section 2.2: Dosage and Administration, Important Monitoring and Administration Instructions

- Prior to initiation of Wegovy®, train patients on proper injection technique.[1] Inspect Wegovy® visually prior to each injection (only use if solution is clear, colorless and contains no particles). Administer Wegovy® subcutaneously once-weekly, on the same day each week, at any time of day, in the abdomen, thigh or upper arm, with or without meals. The time of day and injection site can be changed without dose adjustment.
- In patients with T2D, monitor blood glucose prior to starting Wegovy® and during Wegovy® treatment.[1]

Section 2.3: Dosage and Administration, Recommended Dosage

- In adults and pediatric patients aged 12 years and older, initiate Wegovy® with a dose of 0.25 mg once-weekly and follow the dose escalation schedule in **Figure 1** to minimize gastrointestinal (GI) adverse reactions.[1]



Figure 1. Dose Escalation Schedule[1]

- If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.[1]

Maintenance Dosage – Adult Patients

- The maintenance dose of Wegovy® is 2.4 mg injected subcutaneously once-weekly.[1]
- If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks.[1] After 4 weeks, increase Wegovy® to the maintenance 2.4 mg once-weekly dose. Discontinue Wegovy® if the patient cannot tolerate the 2.4 mg dose.

Maintenance Dosage – Pediatric Patients Aged 12 Years and Older

- The recommended maintenance dose of Wegovy® is 2.4 mg injected subcutaneously once-weekly.[1]
- If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the maintenance dose may be reduced to 1.7 mg once-weekly.[1] Discontinue Wegovy® if the patient cannot tolerate the 1.7 mg dose.

Section 2.4 Dosage and Administration, Recommendations Regarding Missed Dose

- If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer Wegovy® as soon as possible.[1]
- If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.[1]
- If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate Wegovy® and follow the dose escalation schedule (**Figure 1**), which may reduce the occurrence of GI symptoms associated with reinitiation of treatment.[1]

Maximum Dose

Per the Prescribing Information, the maximum recommended dose of Wegovy® is 2.4 mg once-weekly.[1] Novo Nordisk cannot recommend the use of Wegovy® in doses higher than those approved by the United States Food and Drug Administration.

Cessation of Treatment with Wegovy®

At this time, Novo Nordisk does not have a specific recommendation on dosage adjustments during the discontinuation of Wegovy®. Decisions about the prescribing of Novo Nordisk products should be made based on your clinical judgment and an assessment of the benefits versus risks of the therapy in the specific patient.

Appendix A

Body mass index (BMI) cut-offs for obesity in pediatric patients aged 12 years and older, determined based on the CDC age- and sex-specific growth charts, are provided in **Table A.1**.

Table A.1. BMI Cut-offs for Obesity by Sex and Age for Pediatric Patients Aged ≥12 Years (CDC Criteria)[1]

Age (years)	BMI (kg/m^2) at 95th Percentile	
	Males	Females
12	24.2	25.2
12.5	24.7	25.7
13	25.1	26.3
13.5	25.6	26.8
14	26.0	27.2
14.5	26.4	27.7
15	26.8	28.1
15.5	27.2	28.5
16	27.5	28.9
16.5	27.9	29.3
17	28.2	29.6
17.5	28.6	30

Abbreviations: BMI: body mass index; CDC: Centers for Disease Control and Prevention.

References

1. Wegovy® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.